Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
KZIA
Stock Latest News
Ratings
Analyst Maintains Buy Rating on Kazia Therapeutics with Unchanged $34 Price Target on Paxalisib’s Differentiated TNBC Profile
15d ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Files Provisional Patent Backing New Paxalisib Strategy in High-Risk Early TNBC
18d ago
6K
KZIA
Premium
Ratings
Buy Rating Reaffirmed on Kazia as Paxalisib Prospects Strengthen; $30 Price Target Maintained
30d ago
KZIA
Premium
The Fly
Kazia Therapeutics initiated with a Buy at BTIG
2M ago
KZIA
Premium
The Fly
Kazia Therapeutics initiated with a Buy at Lake Street
2M ago
KZIA
Premium
Ratings
Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy
2M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth
2M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics appoints James Levine as CFO
2M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Expands Phase 1b Paxalisib Trial in Advanced Triple-Negative Breast Cancer
3M ago
6K
KZIA
Premium
Company Announcements
Kazia Therapeutics Unveils April 2026 Investor Update Showcasing Multi-Modal Oncology Pipeline
4M ago
6K
KZIA
Premium
Company Announcements
Kazia Therapeutics Names Epigenetics Pioneer Sudha Rao as Chief Scientific Officer to Drive Oncology Platform
4M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer
4M ago
KZIA
Premium
The Fly
Kazia Therapeutics initiated with a Buy at Laidlaw
4M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Licenses SETDB1 Epigenetic Platform to Bolster Oncology Pipeline
4M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer
4M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Announces Board Changes and AGM Outcomes as It Highlights Oncology Pipeline
5M ago
6K
KZIA
Premium
Company Announcements
Kazia Therapeutics Taps Leerink for New ATM Facility as Cash Bolstered by Late-2025 PIPE
5M ago
6K
KZIA
Premium
Company Announcements
Kazia Therapeutics Posts Wider Half-Year Loss but Bolsters Cash, Pipeline and Nasdaq Compliance
5M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics’ NDL2 shows anti-tumor efficacy in preclinical data
7M ago
KZIA
Premium
The Fly
Four new option listings and one option delisting on January 28th
7M ago
KZIA
MICC
Premium
Company Announcements
Kazia Therapeutics Posts Early Efficacy Signals for Paxalisib Combo in Metastatic Triple-Negative Breast Cancer
7M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics’ paxalisib shows clinical response in Phase 1b breast cancer
7M ago
KZIA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
